companydata.dkcompanydata.dk

Ranger Biotechnologies A/S: Financial statements 2022

CVR: 32280404

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

Ranger Biotechnologies A/S (CVR 32280404) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 7,096,093 and a net result of DKK 371,913 compared with DKK 171,975 the year before. That is an increase of 24.3% compared with the year before. Equity in the 2022 report amounted to DKK 1,261,254. The solvency ratio was 47%. The company had 11 employees in the financial year.

Gross Profit
DKK 7,096,093
Profit/Loss
DKK 371,913
Equity
DKK 1,261,254
Total Assets
DKK 2,682,431
Employees
11

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022-7.1M372K1.3M11
2021-5.7M172K889K9
2020-2.4M0717K3
2019-591K-12.7M717K2
2018--832K-975K13.4M1

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Ranger Biotechnologies A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Ranger Biotechnologies A/S: The 2021 annual report is outJun 21, 2022

Ranger Biotechnologies A/S has published its annual report for 2021. Gross profit came to DKK 5,708,942, and the net result was DKK 171,975.

About Ranger Biotechnologies A/S

Ranger Biotechnologies A/S is a Danish company of the type Aktieselskab based in Odense SØ, founded in 2009. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named MIRRX THERAPEUTICS A/S and MIRX THERAPEUTICS A/S. The management consists of Hans Thorleif Møller. The board consists of Christina Møller Udesen (chair), Hans Thorleif Møller, Kasper Tvede Larsen and Søren Tvede Larsen. The company is owned by QUERDENKER ApS and Outlate Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -409,444 and a net result of DKK -843,419 compared with DKK -1,138,092 the year before. Equity in the 2025 report amounted to DKK 711,273.

Source: annual report 2025, Danish Business Authority